Regulatory & Documentation
Protocol Amendment
A protocol amendment is any change to an approved clinical trial protocol that is documented, justified, reviewed by the IRB/EC, and; depending on materiality; submitted to the regulatory authority before implementation.
The Tufts Center for the Study of Drug Development reports that the average Phase III protocol undergoes ~3 amendments, the average Phase II ~2.3, and that ~45% of all amendments are avoidable. The median direct cost of a single amendment is USD 535,000 and the median timeline impact is 3 months.
Substantial amendments (changes to objectives, endpoints, eligibility, dose, or safety reporting) require regulatory and ethics-committee approval before activation; non-substantial amendments (administrative changes, contact updates) typically only require notification.
Amendment risk is concentrated in the first six months after first-patient-in, when operational reality first contradicts protocol assumptions. Pre-finalization protocol review using AI; checking criterion feasibility against real-world data, internal consistency between sections, and historical-amendment patterns; prevents the majority of avoidable amendments.
Related terms
Clinical Trial Protocol
A clinical trial protocol is the master document that defines a clinical study's objectives, design, methodology, statistical considerations, and operational conduct, and that all investigators must follow to ensure scientific validity and participant safety.
ICH M11 (Common Protocol Template)
ICH M11 is the international harmonized standard, published by the International Council for Harmonisation, that defines a Common Protocol Template (CPT) and machine-readable Technical Specification for clinical trial protocols.
See how Kitsa applies this in your trials
Kitsa's agentic AI compresses protocol development, site selection, and patient pre-screening from months into weeks.
Request a demo